Physician profile
Lea Morelle
NPI 1427030014
$5,576.24
in general payments reported to CMS, 2019-2025
19 companies · $3,144 in 2025
The $3,144 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $358 · 2024: $2,074 · 2025: $3,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,576.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $777.81 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $690.22 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $625.72 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $525.18 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $435.35 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $419.16 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $389.48 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $360.66 | 2023-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $359.18 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Tris Pharma INC | $289.47 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Vanda Pharmaceuticals INC. | $242.86 | 2024-2025 | Fanapt |
| Corium, LLC | $107.97 | 2023-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $105.34 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $74.39 | 2024-2025 | Xelstrym |
| Almatica Pharma LLC | $64.77 | 2024-2025 | Loreev Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $38.49 | 2023 | Jornay Pm |
| Alkermes, INC. | $29.39 | 2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $23.49 | 2023 | Adzenys Xr-Odt |
| Tempus Ai, INC | $17.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lea Morelle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.